PTAB statistics
PTAB Statistics: Fiscal Year 2013
In fiscal year 2013 (October 1, 2012 to September 30, 2013), 563 AIA trial petitions were filed: 514 IPR, 0 PGR, 48 CBM and 1 derivation. In the same period the Board instituted trial on 191 petitions and denied 53, an institution rate of 78.3% by petition. The Board issued 1 final written decisions, and 19 proceedings ended in settlement.
Key Facts
- Period
- October 1, 2012 to September 30, 2013
- Petitions filed
- 563
- Institution rate
- 78.3%
- Final written decisions
- 1
- Settlements
- 19
- Data retrieved
- October 31, 2026
On this page
This page reports Patent Trial and Appeal Board trial activity in fiscal year 2013, which ran from October 1, 2012 to September 30, 2013. Each figure is a count of USPTO Open Data Portal records; the methodology on the statistics page explains the counting rules. AIA trials began on September 16, 2012, two weeks before this fiscal year; the 25 petitions filed in those two weeks (17 IPR and 8 CBM) are counted in FY2012 and are not included here.
Figures by Trial Type
Petitions are counted by filing date. Institution decisions, final written decisions and terminations are counted by the date of the event, so a petition filed in one fiscal year may be decided in the next.
| Measure | IPR | PGR | CBM | DER | Total |
|---|---|---|---|---|---|
| Petitions filed | 514 | 0 | 48 | 1 | 563 |
| Institution decisions: instituted | 177 | 0 | 14 | 0 | 191 |
| Institution decisions: denied | 47 | 0 | 6 | 0 | 53 |
| Institution rate (by petition) | 79.0% | — | 70.0% | — | 78.3% |
| Final written decisions | 0 | 0 | 1 | 0 | 1 |
| Terminations without a final written decision | Count |
|---|---|
| Settlements | 19 |
| Adverse judgment | 0 |
| Dismissed | 0 |
| Other terminations | 1 |
Records for this period do not distinguish settlements before institution from those after it, so only the total is shown.
Figures by Trial Type in Detail
Inter Partes Review (IPR)
In FY2013, 514 IPR petitions were filed (91.3% of all AIA petitions). Of 224 IPR institution decisions, 177 instituted a trial and 47 denied institution, a rate of 79.0%. The Board issued 0 IPR final written decisions. An IPR may be instituted only on a reasonable likelihood that the petitioner will prevail on at least one claim (35 U.S.C. § 314(a)), on grounds of anticipation or obviousness over patents and printed publications. See the inter partes review guide for the procedure.
Covered Business Method Review (CBM)
In FY2013, 48 CBM petitions were filed (8.5% of all AIA petitions). Of 20 CBM institution decisions, 14 instituted a trial and 6 denied institution, a rate of 70.0%. The Board issued 1 CBM final written decisions. CBM review applied to covered business method patents and closed to new petitions on September 16, 2020. See the covered business method review guide for the procedure.
Derivation Proceedings (DER)
In FY2013, 1 DER petitions were filed (0.2% of all AIA petitions). No DER institution decisions were recorded. The Board issued 0 DER final written decisions. Derivation proceedings decide whether an inventor named in an earlier application derived the claimed invention from the petitioner’s inventor; they are few in number, so rates rest on small counts. See the guide to the Patent Trial and Appeal Board for the procedure.
How Proceedings Ended
Of the proceedings that ended during the period, 1 ended in a final written decision under 35 U.S.C. § 318, 19 in settlement under 35 U.S.C. § 317, 0 in adverse judgment, 0 by dismissal and 1 by other termination. Denials of institution are counted separately above. A final written decision can lead to estoppel against the petitioner; see estoppel arising from PTAB trials.
Legal and Policy Context
AIA trials began on September 16, 2012, under 35 U.S.C. chapters 31 and 32 and the Board’s rules in 37 C.F.R. Part 42. FY2013 was the first full fiscal year of inter partes review and covered business method review.
These events are noted for context; the statistics alone do not show what caused any change.
Summary
- Inter partes review accounted for 91.3% of petitions filed.
- Of 21 proceedings that ended after institution or by settlement or other termination in the year, 1 (4.8%) ended in a final written decision.
Other Fiscal Years
FY2014 · All fiscal years and charts
Final written decision outcomes (all, some or no challenged claims unpatentable) are not reported because the USPTO records state them for too few decisions; see the methodology. Figures may differ from the USPTO’s published reports. For how trials end and why reported rates differ, see reading PTAB trial outcomes.
Frequently Asked Questions
How many PTAB petitions were filed in FY2013?
In fiscal year 2013 (October 1, 2012 to September 30, 2013), USPTO records show 563 AIA trial petitions: 514 IPR, 0 PGR, 48 CBM and 1 derivation.
What was the PTAB institution rate in FY2013?
By petition, 78.3%: 191 petitions instituted and 53 denied, counted by the date of the institution decision. For IPR alone the rate was 79.0%.
How many final written decisions did the PTAB issue in FY2013?
1, of which 0 were in inter partes reviews. In the same period 19 proceedings settled.
Primary Sources
Related Pages
- GuidePTAB StatisticsUSPTO records show 19,437 AIA trial petitions filed from September 16, 2012 to October 30, 2026: 18,227 inter…
- PTAB statisticsPTAB Statistics: Fiscal Year 2014In fiscal year 2014 (October 1, 2013 to September 30, 2014), 1,493 AIA trial petitions were filed: 1,310 IPR,…
- ArticleReading PTAB Trial Outcomes: Institution, Settlement and Final DecisionsAn AIA trial can end at several points: denial of institution, settlement and termination under 35 U.S.C. §…
- Proceedings guideInter Partes Review (IPR)Inter partes review is a trial before the Patent Trial and Appeal Board in which anyone other than the patent…
- Proceedings guidePost-Grant Review (PGR)Post-grant review lets anyone other than the patent owner challenge an issued patent on almost any ground of…
Educational information; not legal advice. Statutes, rules and USPTO practice change. Confirm against the primary sources and consult a registered patent practitioner before acting. Disclaimer.